explore -WSS

explore

author：explore 2025-09-29 19:58:32 - browse：5

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Inside the rise of 'mukbang' eating videos

WSS

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Eli Lilly’s Mounjaro succeeds in second weight

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Amylyx ALS drug failure raises questions and concerns

The problem with charging patients to message their doctors

focus

explore

focus

Alkermes shareholders re

Bispecific antibodies are next new thing in cancer immunotherapy

Medicare details structure of new drug price negotiation program

Inside the rise of 'mukbang' eating videos

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

New air purifier tech could be key to improving indoor air quality

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Moonlake's readout produced a cash windfall. Risks remain

Bispecific antibodies are next new thing in cancer immunotherapy

hotspot

The thinking behind the controversial eating disorder chatbot Tessa

Millions may soon lose Medicaid when they don't have to

Xenotransplantation trials will require adjusting expectations, experts say

Air quality improving but still lags in Black, Hispanic communities

With psoriasis trial ahead, Alumis raises $259 million

Altering the blood type of lungs raises potential for universal organs for transplants

hotspot

hotspot

leisure time

Wikipedia